Andrzej Pluta

2.3k total citations · 1 hit paper
23 papers, 519 citations indexed

About

Andrzej Pluta is a scholar working on Genetics, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, Andrzej Pluta has authored 23 papers receiving a total of 519 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Genetics, 13 papers in Hematology and 10 papers in Pathology and Forensic Medicine. Recurrent topics in Andrzej Pluta's work include Chronic Lymphocytic Leukemia Research (12 papers), Lymphoma Diagnosis and Treatment (9 papers) and Chronic Myeloid Leukemia Treatments (9 papers). Andrzej Pluta is often cited by papers focused on Chronic Lymphocytic Leukemia Research (12 papers), Lymphoma Diagnosis and Treatment (9 papers) and Chronic Myeloid Leukemia Treatments (9 papers). Andrzej Pluta collaborates with scholars based in Poland, Spain and United States. Andrzej Pluta's co-authors include Martin Šimkovič, Sean Dolan, Abraham Jacob, Daniel Lysák, Wojciech Jurczak, Javier de la Serna, Árpád Illés, Paolo Ghia, Małgorzata Wach and Eric J. Avery and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Hematology.

In The Last Decade

Andrzej Pluta

23 papers receiving 510 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

2020 252 citations Paolo Ghia, Andrzej Pluta et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Andrzej Pluta Poland	8	380	295	186	123	116	23	519
Luciano Levato Italy	13	440 1.2×	257 0.9×	268 1.4×	82 0.7×	189 1.6×	39	659
Maria Grazia Roberti Italy	12	297 0.8×	248 0.8×	153 0.8×	87 0.7×	87 0.8×	21	467
Nilima Parry‐Jones United Kingdom	13	319 0.8×	318 1.1×	61 0.3×	95 0.8×	100 0.9×	21	500
J.J. Sotto France	11	186 0.5×	238 0.8×	148 0.8×	179 1.5×	125 1.1×	17	565
Xavier Calvo Spain	12	388 1.0×	154 0.5×	360 1.9×	219 1.8×	92 0.8×	43	582
Sotirios Sachanas Greece	12	158 0.4×	209 0.7×	109 0.6×	111 0.9×	43 0.4×	34	384
Kerstin Allen United States	13	467 1.2×	472 1.6×	116 0.6×	261 2.1×	248 2.1×	18	754
Emily Hsu United States	8	630 1.7×	527 1.8×	179 1.0×	50 0.4×	223 1.9×	29	705
George P. Keogh United States	6	177 0.5×	156 0.5×	73 0.4×	33 0.3×	68 0.6×	10	323
Lucia Morello Italy	8	324 0.9×	316 1.1×	77 0.4×	84 0.7×	145 1.3×	15	443

Countries citing papers authored by Andrzej Pluta

Since Specialization

Citations

This map shows the geographic impact of Andrzej Pluta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrzej Pluta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrzej Pluta more than expected).

Fields of papers citing papers by Andrzej Pluta

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrzej Pluta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrzej Pluta. The network helps show where Andrzej Pluta may publish in the future.

Co-authorship network of co-authors of Andrzej Pluta

This figure shows the co-authorship network connecting the top 25 collaborators of Andrzej Pluta. A scholar is included among the top collaborators of Andrzej Pluta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrzej Pluta. Andrzej Pluta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cinetto, Francesco, Klaus Fenchel, Riccardo Scarpa, et al.. (2023). Use of immunoglobulin replacement therapy in patients with secondary antibody deficiency in daily practice: a European expert Q&A-based review. Expert Review of Hematology. 16(4). 237–243. 1 indexed citations

Ghia, Paolo, Andrzej Pluta, Małgorzata Wach, et al.. (2022). Acalabrutinib Versus Investigator’s Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results. HemaSphere. 6(12). e801–e801. 65 indexed citations

Mesa, Ruben A., Srđan Verstovšek, Uwe Platzbecker, et al.. (2022). Clinical Outcomes of Myelofibrosis Patients Following Immediate Transition to Momelotinib from Ruxolitinib. Blood. 140(Supplement 1). 3983–3985. 1 indexed citations

Jurczak, Wojciech, Andrzej Pluta, Małgorzata Wach, et al.. (2021). Three-Year Follow-up of the Ascend Trial: Acalabrutinib Vs Rituximab Plus Idelalisib or Bendamustine in Relapsed/Refractory Chronic Lymphocytic Leukemia. Blood. 138(Supplement 1). 393–393. 15 indexed citations

Ghia, Paolo, Andrzej Pluta, Małgorzata Wach, et al.. (2020). ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. Journal of Clinical Oncology. 38(25). 2849–2861. 252 indexed citations breakdown →

Mascarenhas, John, Alessandro M. Vannucchi, Adam J. Mead, et al.. (2020). An Open-Label, Global, Multicenter, Phase 1b/2 Study of KRT-232, a First-in-Class, Oral Small-Molecule Inhibitor of Murine Double Minute 2 (MDM2), Combined with Ruxolitinib in Patients Who Have Myelofibrosis and a Suboptimal Response to Ruxolitinib. Blood. 136(Supplement 1). 44–45. 6 indexed citations

Ghia, Paolo, Andrzej Pluta, Małgorzata Wach, et al.. (2020). CLL-091: Acalabrutinib Versus Idelalisib Plus Rituximab (IdR) or Bendamustine Plus Rituximab (BR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): ASCEND Final Results. Clinical Lymphoma Myeloma & Leukemia. 20. S220–S221. 1 indexed citations

Ghia, Paolo, Andrzej Pluta, Małgorzata Wach, et al.. (2020). Acalabrutinib (Acala) versus idelalisib plus rituximab (IdR) or bendamustine plus rituximab (BR) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): ASCEND final results.. Journal of Clinical Oncology. 38(15_suppl). 8015–8015. 5 indexed citations

Ghia, Paolo, Andrzej Pluta, Małgorzata Wach, et al.. (2019). Acalabrutinib vs Rituximab Plus Idelalisib (IdR) or Bendamustine (BR) by Investigator Choice in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia: Phase 3 ASCEND Study. Clinical Lymphoma Myeloma & Leukemia. 19. S280–S281. 1 indexed citations

10.

Ghia, Paolo, Andrzej Pluta, Małgorzata Wach, et al.. (2019). Acalabrutinib versus Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory CLL: The Randomised, Controlled, Phase 3 ASCEND Trial. SSRN Electronic Journal. 2 indexed citations

11.

McLornan, Donal P., László Rejtő, Éric Jourdan, et al.. (2019). An Open-Label, Phase 2 Study of KRT-232, a First-in-Class, Oral Small Molecule Inhibitor of MDM2, for the Treatment of Patients with Myelofibrosis (MF) Who Have Previously Received Treatment with a JAK Inhibitor. Blood. 134(Supplement_1). 2945–2945. 6 indexed citations

12.

Warzocha, Krzysztof, Wojciech Homenda, Andrzej Pluta, et al.. (2019). Ruksolitynib w terapii chorych na mielofibrozę — pytania i odpowiedzi. Via Medica Journals. 9(4). 269–284. 1 indexed citations

13.

Ghia, Paolo, Andrzej Pluta, Małgorzata Wach, et al.. (2019). Acalabrutinib vs Rituximab Plus Idelalisib (IdR) or Bendamustine (BR) by Investigator Choice in Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia: Phase 3 ASCEND Study. Hematological Oncology. 37(S2). 86–87. 21 indexed citations

14.

Wąsik‐Szczepanek, Ewa, Agnieszka Szymczyk, Dariusz Szczepanek, et al.. (2018). Richter syndrome: A rare complication of chronic lymphocyticleukemia or small lymphocytic lymphoma. Advances in Clinical and Experimental Medicine. 27(12). 1683–1689. 2 indexed citations

15.

Richardson, Paul G., Hervé Avet‐Loiseau, Antonio Palumbo, et al.. (2016). Efficacy and safety of ixazomib plus lenalidomide-dexamethasone (IRd) vs placebo-rd in patients (pts) with relapsed/refractory multiple myeloma (RRMM) by cytogenetic risk status in the global phase III Tourmaline-MM1 study.. Journal of Clinical Oncology. 34(15_suppl). 8018–8018. 7 indexed citations

16.

Flinn, Ian W., Eva Kimby, Finbarr E. Cotter, et al.. (2013). A phase III, randomized, controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with ofatumumab for previously treated chronic lymphocytic leukemia (CLL).. Journal of Clinical Oncology. 31(15_suppl). TPS7131–TPS7131. 18 indexed citations

17.

Hus, Marek, Norbert Grząśko, Andrzej Pluta, et al.. (2011). Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myeloma. Annals of Hematology. 90(10). 1161–1166. 49 indexed citations

18.

Kübler, Andrzej, et al.. (2004). Severe sepsis in Poland--results of internet surveillance of 1043 cases.. PubMed. 10(11). CR635–41. 18 indexed citations

19.

Pluta, Andrzej & L Szczepański. (2003). Reumatoidalne zapalenie stawów - zasady leczenia. Przewodnik Lekarza/Guide for GPs. 4(10). 22–28. 1 indexed citations

20.

Pluta, Andrzej, et al.. (1990). Normal B cell compartment in chronic lymphatic leukemia. Hematological Oncology. 8(3). 121–124. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact